PetVivo receives final $1M from $5M Series B Convertible Preferred Stock offering

PetVivo Holdings, Inc.

Received $1M from full exercise of Purchase Option, completing $5M equity financing.
Total of $5M raised via Series B Convertible Preferred Stock at $1 per share, convertible 1:1 into common stock.
Proceeds intended for commercialization of Spryng and PrecisePRP, clinical trials, and working capital.
Sale made under Section 4(a)(2) to accredited investor; shares are restricted.
Certificate of Designation filed on March 26, 2025; amendment on March 31, 2025 for Company Call Option.

item 1.01item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.